Tropanserin

Tropanserin is a serotonin antagonist and reuptake inhibitor (SARI) that was first synthesized in the 1980s by Hoffmann-La Roche. It was developed as a potential treatment for depression and anxiety, but was never marketed.

History

Tropanserin was first synthesized in the 1980s by the pharmaceutical company Hoffmann-La Roche. Despite showing promise as a potential treatment for depression and anxiety, the drug was never marketed.

Pharmacology

Tropanserin acts as a serotonin antagonist and reuptake inhibitor (SARI). This means it blocks the action of serotonin, a neurotransmitter that is involved in mood regulation, and also prevents its reuptake, or reabsorption, into the nerve cells. This increases the amount of serotonin available in the brain, which can help to alleviate symptoms of depression and anxiety.

Clinical Trials

While Tropanserin was never marketed, it did undergo clinical trials. These trials showed that the drug had a similar efficacy to other antidepressants available at the time, but with fewer side effects. However, for reasons that are not entirely clear, Hoffmann-La Roche decided not to pursue the development of Tropanserin further.

See Also

• Serotonin antagonist
• Reuptake inhibitor
• Depression
• Anxiety
• Hoffmann-La Roche

Tropanserin Resources
Latest articles Most recent articles Ongoing trials	Wikipedia